A Randomized, Double-blind, Crossover Study to Assess the Effects of LCZ696 and Valsartan in Asian Patients With Salt-sensitive Hypertension

Trial Profile

A Randomized, Double-blind, Crossover Study to Assess the Effects of LCZ696 and Valsartan in Asian Patients With Salt-sensitive Hypertension

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jan 2017

At a glance

  • Drugs Sacubitril/valsartan (Primary) ; Valsartan
  • Indications Essential hypertension
  • Focus Pharmacodynamics
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 15 Jun 2015 Results presented at the 25th European Meeting on Hypertension and Cardiovascular Protection.
    • 15 Jun 2015 Primary endpoint has been met. (Cumulative Sodium excretion (natriuresis) [ Time Frame: 6 hour following the first dose of LCZ696 and valsartan ]) as per abstract presented at 25th European Meeting on Hypertension and Cardiovascular Protection.
    • 15 Jun 2015 Primary endpoint has been met. (Cumulative Sodium excretion (natriuresis) [ Time Frame: 24 hour following the first dose of LCZ696 and valsartan ]) as per abstract presented at 25th European Meeting on Hypertension and Cardiovascular Protection.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top